DFTX
Definium Therapeutics, Inc.
A clinical-stage biopharmaceutical company in New York City developing psychedelic-based medicines for psychiatric and neurological disorders. Founded in 2019 as MindMed, a startup exploring LSD and other psychedelics as therapies, it rebranded to Definium Therapeutics in 2026. Its lead program, DT120, is an orally disintegrating tablet of lysergide (LSD) designed to dissolve on the tongue.
CUSIP: 24477V105HealthcareUS1 holder
Total Value
$30.14M
Total Shares
1.59M
Net Share Change
+1.59M
Activity
1 buying
Investor
Value
Shares
Weight
Change
